Free Trial

BGM Group (BGM) Competitors

$10.95 +1.10 (+11.17%)
Closing price 04:00 PM Eastern
Extended Trading
$10.96 +0.01 (+0.05%)
As of 05:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BGM vs. KYMR, HCM, MOR, ALVO, AMRX, RARE, MIRM, CPRX, OGN, and ARWR

Should you be buying BGM Group stock or one of its competitors? The main competitors of BGM Group include Kymera Therapeutics (KYMR), HUTCHMED (HCM), MorphoSys (MOR), Alvotech (ALVO), Amneal Pharmaceuticals (AMRX), Ultragenyx Pharmaceutical (RARE), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), Organon & Co. (OGN), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry.

BGM Group vs. Its Competitors

Kymera Therapeutics (NASDAQ:KYMR) and BGM Group (NASDAQ:BGM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Kymera Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the S&P 500. Comparatively, BGM Group has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.

In the previous week, Kymera Therapeutics had 3 more articles in the media than BGM Group. MarketBeat recorded 5 mentions for Kymera Therapeutics and 2 mentions for BGM Group. Kymera Therapeutics' average media sentiment score of 0.76 beat BGM Group's score of 0.00 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kymera Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BGM Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Kymera Therapeutics currently has a consensus target price of $59.11, suggesting a potential upside of 28.92%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kymera Therapeutics is more favorable than BGM Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kymera Therapeutics
0 Sell rating(s)
1 Hold rating(s)
17 Buy rating(s)
2 Strong Buy rating(s)
3.05
BGM Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

BGM Group has lower revenue, but higher earnings than Kymera Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera Therapeutics$47.07M63.43-$223.86M-$3.10-14.79
BGM Group$25.10M42.41-$1.44MN/AN/A

BGM Group has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -409.07%. BGM Group's return on equity of 0.00% beat Kymera Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kymera Therapeutics-409.07% -30.11% -25.65%
BGM Group N/A N/A N/A

Summary

Kymera Therapeutics beats BGM Group on 9 of the 13 factors compared between the two stocks.

Get BGM Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for BGM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BGM vs. The Competition

MetricBGM GroupMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.06B$3.06B$5.67B$9.49B
Dividend YieldN/A2.44%4.05%4.00%
P/E RatioN/A20.8627.9419.95
Price / Sales42.41246.06396.5882.68
Price / CashN/A41.9636.1958.45
Price / Book1.498.308.635.82
Net Income-$1.44M-$55.19M$3.24B$258.42M
7 Day Performance13.47%5.07%3.22%1.94%
1 Month Performance-15.18%17.61%10.72%12.02%
1 Year PerformanceN/A7.03%34.94%20.80%

BGM Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BGM
BGM Group
N/A$10.95
+11.2%
N/AN/A$1.06B$25.10M0.00298News Coverage
Gap Up
High Trading Volume
KYMR
Kymera Therapeutics
3.1557 of 5 stars
$44.31
-1.3%
$59.11
+33.4%
+6.8%$2.88B$47.07M-14.25170
HCM
HUTCHMED
2.8081 of 5 stars
$16.38
+0.9%
$19.00
+16.0%
-7.0%$2.86B$630.20M0.001,811Analyst Forecast
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
ALVO
Alvotech
2.8765 of 5 stars
$8.84
-0.7%
$18.00
+103.7%
-22.4%$2.65B$585.60M23.751,032High Trading Volume
AMRX
Amneal Pharmaceuticals
3.2932 of 5 stars
$8.38
-0.4%
$11.60
+38.4%
+8.6%$2.62B$2.79B-209.328,100
RARE
Ultragenyx Pharmaceutical
4.3494 of 5 stars
$27.77
-5.0%
$83.64
+201.3%
-38.0%$2.62B$560.23M-4.721,294Upcoming Earnings
MIRM
Mirum Pharmaceuticals
3.9526 of 5 stars
$52.03
-2.4%
$65.50
+25.9%
+32.0%$2.58B$336.89M-32.36140Positive News
CPRX
Catalyst Pharmaceuticals
4.9136 of 5 stars
$21.05
-2.6%
$32.83
+56.0%
+22.8%$2.56B$491.73M13.3980News Coverage
Positive News
OGN
Organon & Co.
4.8521 of 5 stars
$9.66
-1.5%
$18.00
+86.4%
-53.0%$2.51B$6.40B3.354,000
ARWR
Arrowhead Pharmaceuticals
3.879 of 5 stars
$18.12
-2.6%
$43.71
+141.2%
-44.7%$2.50B$545.21M-12.94400Positive News

Related Companies and Tools


This page (NASDAQ:BGM) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners